Alx Oncology Holdings INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
ALX Oncology's 10-K filing highlights positive Phase 2 clinical data for evorpacept and outlines plans for new clinical trials in breast and colorectal cancer.
NASDAQ
ALX Oncology's 10-K filing outlines the company's capital structure, including common and preferred stock, and details registration rights for certain shareholders.